Hudson Bay Capital Management
MRVI icon

Hudson Bay Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Hudson Bay Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-349,663
Closed -$1M – 1424
2025
Q3 		$1M Sell
349,663
-78,654
-18% -$201K ﹤0.01% 863
2025
Q2 		$1.03M Hold
428,317
– – ﹤0.01% 955
2025
Q1 		$947K Buy
428,317
+213,074
+99% +$842K ﹤0.01% 933
2024
Q4 		$1.17M Buy
215,243
+87,846
+69% +$565K ﹤0.01% 722
2024
Q3 		$1.06M Sell
127,397
-345,396
-73% -$2.99M ﹤0.01% 666
2024
Q2 		$3.39M Sell
472,793
-63
-0% -$544 0.02% 449
2024
Q1 		$4.1M Sell
472,856
-1,197,085
-72% -$8.1M 0.02% 342
2023
Q4 		$10.9M Buy
1,669,941
+1,010,544
+153% +$6.53M 0.07% 168
2023
Q3 		$6.59M Buy
659,397
+416,876
+172% +$4.58M 0.05% 230
2023
Q2 		$3.01M Buy
+242,521
New +$3.27M 0.02% 423
2021
Q4 		– Sell
-90,000
Closed -$4.42M – 1161
2021
Q3 		$4.42M Buy
+90,000
New +$4.39M 0.06% 394

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hudson Bay Capital Management's MRVI Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 349,663 shares — an estimated $1M sold.

Hudson Bay Capital Management first reported a position in MRVI in Q3 2021 and held it in 11 quarters. The position peaked at $10.9M in Q4 2023. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

  • Hudson Bay Capital Management reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 349,663 Maravai LifeSciences shares in Q4 2025, an estimated $1M.
  • Hudson Bay Capital Management first reported a position in Maravai LifeSciences in Q3 2021 and held it in 11 quarters.
  • Hudson Bay Capital Management's Maravai LifeSciences position peaked at $10.9M in Q4 2023.
  • 159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.